1993 Fiscal Year Final Research Report Summary
Fundamental study of neuronal cell differentiation system by transfection with glial fibrillary acidic protein gene.
| Project/Area Number |
04670859
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
WAKABAYASHI Toshihiko Nagoya University School of Medicine, Assistant, 医学部, 助手 (50220835)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOSHIDA Jun Nagoya University School of Medicine, Assistant Professor, 医学部, 講師 (40158449)
|
|---|
| Project Period (FY) |
1992 – 1993
|
| Keywords | GFAP / Gene transfection, / Brain tumor |
|---|
| Research Abstract |
Glial fibrillary acidic protein (GFAP) is one of the intermediate filaments which was found in mature normal astrocytes and differentiated glioma cells It seems to stabilize the astrocyte's cytoskeleton and help maintain astrocyte cell shape together with other cytoskeletal components such as microfilament and microtubule, however its tissue-specific role is not clear. To verify the effect of GAFP expression in brain tumor cell, transfer of GFAP gene into human medulloblastoma cell line (DAOY-1) which dose not express GFAP was performed by means of liposomes. After tranfection, we studied the alteration of chracteristics in GFAP transfected cells. Cell growth, morphology and sensitivity of cytokine or anticancer drugs were compared between GFAP transfected and non-transfected cells. As a result, the GFAP gene transfected cells demonstrated that, 1) Growth inhibition, 2) Increase of sensitivity to some anticancer drugs such as ACNU and Cisplatinum, 3) High expression of tumor related cell surface antigen such as G-22, which is known as one of the intercellular adhesion molecule, 4) although morphological changes was not apparent. These results suggest that GFAP gene transfected cell has a possibility to be more sensitive for the anticancer drugs, and it is expected the clinical application for the treatment of malignant brain tumors.
|
